233 related articles for article (PubMed ID: 34605346)
1. Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients.
Bach S; Wever BMM; van de Wiel MA; Veltman JD; Hashemi SMS; Kazemier G; Bahce I; Steenbergen RDM
Epigenetics; 2022 Oct; 17(10):1057-1069. PubMed ID: 34605346
[TBL] [Abstract][Full Text] [Related]
2. Detection of non-metastatic non-small-cell lung cancer in urine by methylation-specific PCR analysis: A feasibility study.
Wever BMM; Bach S; Tibbesma M; Ter Braak TJ; Wajon D; Dickhoff C; Lissenberg-Witte BI; Hulbert A; Kazemier G; Bahce I; Steenbergen RDM
Lung Cancer; 2022 Aug; 170():156-164. PubMed ID: 35793574
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
[TBL] [Abstract][Full Text] [Related]
4. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation biomarkers discovered
Vrba L; Oshiro MM; Kim SS; Garland LL; Placencia C; Mahadevan D; Nelson MA; Futscher BW
Epigenetics; 2020 Apr; 15(4):419-430. PubMed ID: 31775567
[TBL] [Abstract][Full Text] [Related]
7. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
[TBL] [Abstract][Full Text] [Related]
8. Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer.
Liu B; Ricarte Filho J; Mallisetty A; Villani C; Kottorou A; Rodgers K; Chen C; Ito T; Holmes K; Gastala N; Valyi-Nagy K; David O; Gaba RC; Ascoli C; Pasquinelli M; Feldman LE; Massad MG; Wang TH; Jusue-Torres I; Benedetti E; Winn RA; Brock MV; Herman JG; Hulbert A
Clin Cancer Res; 2020 Aug; 26(16):4339-4348. PubMed ID: 32430478
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.
Balgkouranidou I; Chimonidou M; Milaki G; Tsarouxa EG; Kakolyris S; Welch DR; Georgoulias V; Lianidou ES
Br J Cancer; 2014 Apr; 110(8):2054-62. PubMed ID: 24642624
[TBL] [Abstract][Full Text] [Related]
10. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.
Tóth K; Patai ÁV; Kalmár A; Barták BK; Nagy ZB; Galamb O; Wichmann B; Tulassay Z; Molnár B
Pathol Oncol Res; 2017 Jul; 23(3):699-706. PubMed ID: 28035516
[TBL] [Abstract][Full Text] [Related]
11. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
[TBL] [Abstract][Full Text] [Related]
12. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
13. HOXA9 gene promotor methylation and copy number variation of SOX2 and HV2 genes in cell free DNA: A potential diagnostic panel for non-small cell lung cancer.
Abou-Zeid A; Hashad D; Baess A; Mosaad M; Tayae E
BMC Cancer; 2023 Apr; 23(1):329. PubMed ID: 37038139
[TBL] [Abstract][Full Text] [Related]
14. A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles.
Kim YJ; Jeon H; Jeon S; Lee SH; Kim C; Ahn JH; Um H; Woo YJ; Jeong SH; Kim Y; Park HY; Oh HJ; Cho HJ; Bae JH; Kim JH; An S; Kang SB; Jho S; Biro O; Kis D; Kim BC; Kim Y; Kim JH; Kim BC; Bhak J; Oh IJ
Mol Cell Probes; 2022 Dec; 66():101873. PubMed ID: 36379302
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
Ghosh M; Mukhopadhyay M; Das C; Chatterjee S; Naskar BG
J Cancer Res Ther; 2021; 17(6):1389-1396. PubMed ID: 34916369
[TBL] [Abstract][Full Text] [Related]
16. The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
Shen Z; Chen C; Sun J; Huang J; Liu S
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2239-2248. PubMed ID: 34037837
[TBL] [Abstract][Full Text] [Related]
17. Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies.
Magenheim J; Rokach A; Peretz A; Loyfer N; Cann G; Amini H; Moradi P; Nagaraju S; Sameer W; Cohen A; Fogel O; Kuint R; Abutbul A; Abu Rmeileh A; Karameh M; Cohen Goichman P; Wald O; Korach A; Neiman D; Fox-Fisher I; Moss J; Cohen D; Piyanzin S; Ben Ami R; Quteineh A; Golomb E; Shemer R; Glaser B; Kaplan T; Fridlender ZG; Dor Y
Eur Respir J; 2022 Nov; 60(5):. PubMed ID: 35450968
[TBL] [Abstract][Full Text] [Related]
18. Serum circulating free DNA of syncytin-1 as a novel molecular marker for early diagnosis of non-small-cell lung cancer.
Zhuang X; Qian J; Xia X; Wang Y; Wang H; Jing L; Zhang Y; Zhang Y
Biomark Med; 2022 Dec; 16(18):1259-1268. PubMed ID: 36861469
[No Abstract] [Full Text] [Related]
19. Genome-Wide Plasma Cell-Free DNA Methylation Profiling Identifies Potential Biomarkers for Lung Cancer.
Xu W; Lu J; Zhao Q; Wu J; Sun J; Han B; Zhao X; Kang Y
Dis Markers; 2019; 2019():4108474. PubMed ID: 30867848
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients.
Zhou X; Li C; Zhang Z; Li DY; Du J; Ding P; Meng H; Xu H; Li R; Ho E; Zhang A; Okunieff P; Lu J; Sha MY
Sci Rep; 2021 Apr; 11(1):7633. PubMed ID: 33828112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
